SCIENTIST, EDUCATOR, INNOVATOR
Scientific and translational leader with 19+ years advancing immunology, hematology, oncology, and rare disease programs from discovery through early development. Senior Director at Moderna, driving platform and portfolio strategy across delivery, chemistry, biology, and AI-enabled R&D to accelerate decision-making and program execution. Scientific co-founder of Magenta Therapeutics and former Harvard Medical School faculty/NIH-funded PI, with a track record translating high-impact biology into clinical-stage innovation and venture-backed company building. Recognized leader in non-viral delivery and gene therapy scientific strategy (ASH/ASGCT), known for building high-performing cross-functional teams and partnering with executive leadership and boards. Earlier public-sector leadership as a Police Commissioner and City Councilor brings direct experience in governance, budget discipline, and complex people leadership.
SCIENTIST, EDUCATOR, INNOVATOR
Scientific and translational leader with 19+ years advancing immunology, hematology, oncology, and rare disease programs from discovery through early development. Senior Director at Moderna, driving platform and portfolio strategy across delivery, chemistry, biology, and AI-enabled R&D to accelerate decision-making and program execution. Scientific co-founder of Magenta Therapeutics and former Harvard Medical School faculty/NIH-funded PI, with a track record translating high-impact biology into clinical-stage innovation and venture-backed company building. Recognized leader in non-viral delivery and gene therapy scientific strategy (ASH/ASGCT), known for building high-performing cross-functional teams and partnering with executive leadership and boards. Earlier public-sector leadership as a Police Commissioner and City Councilor brings direct experience in governance, budget discipline, and complex people leadership.
Moderna
Senior Director Platform & Program Strategy, AI Integration
Mar 2021 – Present
Magenta Therapeutics
Scientific Co-founder
Nov 2016
Harvard Stem Cell Institute
Principal Faculty
Jun 2015 – Mar 2022
Harvard Medical School
Assistant Professor of Medicine
Jun 2015 – Mar 2022
Harvard University
Affiliate Faculty Member
Stem Cell and Regenerative Biology
Jun 2015 – Mar 2022
Harvard University
Postdoctoral Fellow
Jun 2011 – Jun 2015
City of West Lafayette
City Councilor
Oct 2009 – May 2011
City of West Lafayette
Police Commissioner
Mar 2006 – Oct 2009
[ EDUCATION ]
HARVARD UNIVERSITY
Post-Doctoral Fellowship,
Stem Cell Biology
2011 – 2015
Indiana University School of Medicine
Doctor of Philosophy (Ph.D.), Immunology
2006 – 2010
Indiana University–Purdue University Indianapolis
Master’s Degree, Biology
2005 – 2006
PURDUE UNIVERSITY
Bachelor’s Degree, Pharmaceutical Sciences
2001 – 2005
[ SKILLS ]
[ HONORS & AWARDS ]
“Wall of Pride” April 2024
American Society of Hematology Scholar Award
Issued by American Society of Hematology · Jul 2019
Research Rumble Champion
Issued by Mass General Brigham / Cambridge Science Festival · Apr 2017
Thomas T. Hoopes Prize Mentor Award
Issued by Harvard University · May 2016
Thomas T. Hoopes Prize Mentor Award
Issued by Harvard University · May 2013
Esther L. Kinsley Ph.D. Dissertation Award
Issued by Indiana University · May 2010
SELECT 15 OF 57
[ PUBLICATIONS ]
Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden DT, Guise T, Srour EF, Pelus, LM. “Differential Stem and Progenitor Cell Trafficking by Prostaglandin E2”. Nature 2013, Mar 21;495(7441):365-9.
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK,Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ. “Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.” Nature Communications, 2019; Feb6;10(1):617-628.
Broxmeyer HE*, Hoggatt J*, O’Leary HA, Mantel C, Chitteti BR, Cooper S, Messina-Graham S, Hangoc G, Farag S, Rohrabaugh SL, Ou X, Speth JM, Pelus LM, Srour EF, Campbell TB. “CD26/Dipeptidylpeptidase IV Negatively Regulates Colony Stimulating Factor Activity and Stress Hematopoiesis”. Nature Medicine 2012, Dec;18(12):1786-9. *co-first authors
Hoggatt J*, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, Liu L, Kharchenko PV, Schajnovitz A, Baryawno N, Mercier FE, Boyer J, Gardner J, Morrow DM, Scadden DT, Pelus LM. “Rapid mobilization reveals a highly engraftable hematopoietic stem cell.” Cell, 2018; Jan11;172(1-2):191-204. *lead corresponding author
Menendez-Gonzalez JB and Hoggatt J. “Hematopoietic Stem Cell Mobilization: Current Collection Approaches, Stem Cell Heterogeneity, and a Proposed New Method for Stem Cell Transplant Conditioning.” Stem Cell Reviews and Reports, 2021 Dec;17(6):1939-1953.
Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Tate TA, Czechowicz A, Kfoury Y, Ruchika F, Rossi DJ, Verdine GL, Mansour MK, Scadden DT. “Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic cell-specific internalizing immunotoxin.” Nature Biotechnology, 2016 Jul;34(7):738-745.
Hoggatt J, Singh P, Stilger KN, Plett PA, Sampson CH, Chua HL, Orschell CM, Pelus LM. “Recovery from hematopoietic injury by modulating prostaglandin E(2) signaling post-irradiation.” Blood Cells Molecule and Diseases 2013;50(3):147-53.
Hoggatt J*, Tate TA and Pelus LM*. “Hematopoietic Stem and Progenitor Cell Mobilization in Mice.” 3rd Edition Hematopoietic Stem Cell Protocols, Methods in Molecular Medicine, Humana Press, 2014;1185:43-64. *co-corresponding authors
Hoggatt J, Mohammad KS, Singh P, Pelus LM. “Prostaglandin E2 Enhances Long-term Repopulation but Does Not Permanently Alter Inherent Stem Cell Competitiveness.” Blood 2013;122(17):2997 – 3000.
Hoggatt J*+, Hoggatt AF*, Tate TA, Fortman J, Pelus LM+. “Bleeding the Laboratory Mouse: Not All Methods are Equal.” Experimental Hematology, 2016: Feb;44(2):132-137.
*co-first authors
Hoggatt J, Pelus LM. “Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking.” Leukemia 2010;24(12):1993-2002.
Hoggatt J, Scadden DT. “The Stem Cell Niche: Tissue Physiology at a Single Cell Level.” Journal of Clinical Investigation 2012;122(9):3029-34.
Hoggatt J, Singh P, Sampath J, Pelus LM. “Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation”. Blood 2009;113(22):5444-55.
Hoggatt J, Kfoury Y and Scadden DT. “Hematopoietic Stem Cell Niche in Health and Disease.” Annual Review of Pathology, 2016;11:555-581.
Hoggatt J. “Gene Therapy for ‘Bubble Boy’ Disease.” Cell, 2016; Jul 14;166(2):263.
[ PATENTS ]
[ PRESS ]
Helping People in Need of a Stem Cell Transplant
In certain people with cancer or other serious diseases, transplants of healthy adult stem cells can be lifesaving. But donating blood-forming stem cells is a bit more complicated than giving blood. For example, stem-cell donors most often undergo five days of injections to build up enough of those vital cells in the blood for
Harvard stem cell research lead Jonathan Hoggatt joins Moderna as Director of Hematology
Moderna has poached major stem cell researcher Jonathan Hoggatt, Ph.D., to lead its hematology R&D as it gears up for a future outside of COVID vaccines.
Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know
Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team. What Happened: Jonathan Hoggatt, who was a principal faculty member at Harvard Stem Cell Institute, has...
What Defines a Stem Cell? Scientists Rethink the Answer | Quanta Magazine
After several puzzling discoveries have proven that certain stem cell populations are not stem cells at all, or that some differentiated adult cells are able to revert to a stem-like state in certain situations, scientists are redefining what it means to be a stem cell. Dr. Hans Clevers, Dr. Jonathan Hoggatt, and Dr. Pamela Robey discuss “stemness” in this piece by Jordana Cepelewicz of Quanta Magazine.
Welcome to the Age of One-Shot Miracle Cures That Can Cost Millions
Gene therapy appears to successfully treat once-incurable patients like “bubble boy”. Dr. Hoggatt is interviewed in the Bloomberg piece by Michelle Fay Cortez.
Five Things to Know About Bone Marrow and Stem Cell Harvest
Researchers at Mass General and Indiana University have developed a new method for harvesting bone marrow stem cells that could be a game changer.
Get your money back if pricey new gene therapy doesn't cure you
ADA-SCID, commonly known as bubble boy disease, is an immune system disease caused by a mutation in the adenosine deaminase gene. GlaxoSmithKline has developed a new gene editing therapy called Strimvelis, with a money back guarantee. Read more in this CNN article by Susan Scutti, featuring commentary by Dr. Hoggatt.
Gun Violence: A Public Health Crisis
Gun Violence: A Public Health Crisis - Dr. Hoggatt discusses the implications of medical and scientific advocacy.
Farming Hematopoietic Stem Cells with Drs. Jonathan Hoggatt & George Daley by The Hematologist
In his Diffusion article from the September/October 2017 issue of The Hematologist, Dr. Jonathan Hoggatt discusses efforts to grow hematopoietic stem cells to care for patients with diseases that can
